Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Stukalin

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Current Oncology (Toronto, Ont.)|October 22, 2021
Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy DatabaseHeidi A I Grosjean, Samantha Dolter, Daniel E Meyers, et al.
Clinical Lung Cancer|February 11, 2023
Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint BlockadeVishal Navani, Daniel E Meyers, Yibing Ruan, et al.
The Oncologist|April 3, 2023
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint InhibitorsIgor Stukalin, Vishal Navani, Mehul Gupta, et al.
Clinical Genitourinary Cancer|October 21, 2018
Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted TherapiesNils Kroeger, Haoran Li, Guillermo De Velasco, et al.
Clinical Genitourinary Cancer|April 17, 2021
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world StudyJ Connor Wells, Shaan Dudani, Chun Loo Gan, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2021
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trialsChun L Gan, Igor Stukalin, Daniel E Meyers, et al.
European Urology|June 20, 2016
Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumJ Connor Wells, Igor Stukalin, Craig Norton, et al.
European Urology Oncology|February 11, 2020
Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumFrede Donskov, Wanling Xie, Anders Overby, et al.
Journal for Immunotherapy of Cancer|March 3, 2025
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective studyAmin H Nassar, Sarah Abou Alaiwi, Talal El Zarif, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Current Oncology (Toronto, Ont.)|October 22, 2021
Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy DatabaseHeidi A I Grosjean, Samantha Dolter, Daniel E Meyers, et al.
Clinical Lung Cancer|February 11, 2023
Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint BlockadeVishal Navani, Daniel E Meyers, Yibing Ruan, et al.
The Oncologist|April 3, 2023
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint InhibitorsIgor Stukalin, Vishal Navani, Mehul Gupta, et al.
Clinical Genitourinary Cancer|October 21, 2018
Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted TherapiesNils Kroeger, Haoran Li, Guillermo De Velasco, et al.
Clinical Genitourinary Cancer|April 17, 2021
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world StudyJ Connor Wells, Shaan Dudani, Chun Loo Gan, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2021
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trialsChun L Gan, Igor Stukalin, Daniel E Meyers, et al.
European Urology|June 20, 2016
Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumJ Connor Wells, Igor Stukalin, Craig Norton, et al.
European Urology Oncology|February 11, 2020
Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumFrede Donskov, Wanling Xie, Anders Overby, et al.
Journal for Immunotherapy of Cancer|March 3, 2025
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective studyAmin H Nassar, Sarah Abou Alaiwi, Talal El Zarif, et al.
Pageof 4